Adjuvant intravesical mitoxantrone versus recombinant interferon-α after transurethral resection of superficial bladder cancer: A randomized prospective study

Urologia Internationalis

Volumn 72, Issue 4, 2004, Pages 284-291

  Papatsoris, A G ^a,c   Deliveliotis, C ^b   Giannopoulos, A ^b   Dimopoulos, C ^b  

^a 'Agios Andreas' Reg Hosp of Patras   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c NONE   (Greece)

Author keywords

Interferon ; Intravesical therapy; Mitoxantrone; Superficial bladder cancer

Indexed keywords

MITOXANTRONE; RECOMBINANT ALPHA INTERFERON;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; ARTICLE; BLADDER CANCER; CANCER RECURRENCE; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; LEG RASH; MAJOR CLINICAL STUDY; MALE; NAUSEA; PENIS DISEASE; PRIORITY JOURNAL; RASH; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SUPERFICIAL CANCER; TOXICITY; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; TUMOR GROWTH; VOMITING;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; INTERFERON TYPE I, RECOMBINANT; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 2942525964     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077679     Document Type: Article

References (25)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics. CA Cancer J Clin 1999;49:8-31.
2. Droller MJ: Bladder cancer: State-of-the-art care. CA Cancer J Clin 1998;48:269-284.
3. Melekos MD, Moutzouris GD: Intravesical therapy of superficial bladder cancer. Curr Pharm Des 2000;6:345-359.
4. Oosterlinck W, Lobel B, Jakse G, Malmstrom P, Stockle M, Strenberg C: Guidelines on bladder cancer. Eur Urol 2002;41:105-112.
5. Nawrocki S, Skacel T, Skoneczna I: Pharmacotherapy of bladder cancer - Practice and prospects. Expert Opin Pharmacother 2002;3:671-679.
6. Herr HW: Natural history of superficial bladder tumours: 10- to 20-year follow-up of treated patients. Word J Urol 1997;15:84-88.
7. Oosterlinck W: The management of superficial bladder cancer. BJU Int 2001;87:135-140.
8. Baselli EC, Greenberg RE: Intravesical therapy for superficial bladder cancer. Oncology (Huntingt) 2000;14:719-729.
9. Hepburn PJ, Oliver RTD, Riley PA, Hill BT, Masters JRW: Comparison of the cytotoxic activities of chemotherapeutic drugs using a human bladder cancer cell line. Urol Res 1984;13:27-34.
10. Giannopoulos A, Constantinides C, Kortsaris A, Chrisofos M, Pavlaki C, Dimopoulos C: Determination of interferon-α receptors in urothelial cancer and in normal urothelium. J Urol 1997;157:79-82.
11. Giannakopoulos S, Gekas A, Alivizatos G, Sofras F, Becopoulos T, Dimopoulos C: Efficacy of escalating doses of intravesical interferon-α2b in reducing recurrence rate and progression in superficial transitional cell carcinoma. Br J Urol 1998;82:829-834.
12. Da Silva FC, Furtado L, Reis M, Carreira F, Dias V, Oliveira G: Comparison of two doses of interferon-α2b in intravesical prophylaxis of superficial bladder tumors. Portuguese Genito-Urinary Group. Eur Urol 1995;28:291-296.
13. Sharifi R, Lee M, Clayton M, et al: Phase I-II evaluation of intravesical Novatrone (mitoxantrone) in superficial bladder cancer. Anticancer Drugs 1991;2:153-157.
14. Yaman LS, Yurdakul T, Zissis NP, Arikan N, Yasar B: Intravesical mitoxantrone for superficial bladder tumors. Anticancer Drugs 1994;5:95-98.
15. Namasivayam S, Whelan P: Intravesical mitozantrone in recurrent superficial bladder cancer. Br J Urol 1995;75:740-743.
16. Stewart DJ, Green R, Futter N, et al: Phase I and pharmacology study of intravesical mitoxantrone for recurrent superficial bladder tumors. J Urol 1990;143:714-716.
17. Davis JW, Sheth SI, Doviak MJ, Schellhammer PF: Superficial bladder carcinoma treated with bacillus Calmette-Guérin: Progression-free and disease-specific survival with minimum 10-year follow-up. J Urol 2002;167:494-500.
18. Kostakopoulos A, Deliveliotis C, Mavromanolakis E, Aravantinos G, Dimopoulos MA: Intravesical interferon-α2b administration in the treatment of superficial bladder tumors. Eur Urol 1990;18:201-203.
19. Serretta V, Corselli G, Pavone C, Pavone-Macaluso M: Intravesical mitoxantrone in superficial bladder tumours (Ta-T1). Eur J Cancer 1993;29:1899-1900.
20. Portillo J, Martin B, Hernandez R, et al: Results at 43 months' follow-up of a double-blind, randomised, prospective critical trial using intravesical interferon-α2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. Urology 1997;49:187-190.
21. Brown DH, Wagner TT, Bahnson RR: Interferons and bladder cancer. Urol Clin North Am 2000;27:171-178.
22. Amling CL: Diagnosis and management of superficial bladder cancer. Curr Probl Cancer 2001;25:219-278.
23. Duque JLF, Loughlin KR: An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy. Superficial bladder cancer: New strategies in diagnosis and treatment. Urol Clin North Am 2000;27:125-135.
24. Belldegrun AS, Franklin JR, O'Donnell MA, et al: Superficial bladder cancer: The role of interferon-α. J Urol 1998;159:1793-1801.
25. Kurth KH, Bouffioux C, Sylvester R, Van der Meijden APM, Oosterlinck W, Brausi M: Treatment of superficial bladder cancer: Achievements and needs. The EORTC Genitourinary Group. Eur Urol 2000;37:1-9